We are working with The Sage Group to help us find partners to use our biomarker discovery platform to develop more predictive autoantibody marker panels. (For more details see our press release.)

Please email Dr. Bill Mason at The Sage Group if you would like to recive a presentation outlining the technology or to discuss your proposed programme in more depth.

Alternatively, please contact us direct if you would prefer.

Collaborations may involve:

• discovering disease-specific panels of autoantibodies
• developing clinical diagnostics based on disease-specific autoantibody panels
• discovering autoantibody panels to monitor drug efficacy in clinical trials
• discovering autoantibody panels resulting from immunogenic responses to therapeutic agents
• developing the use of autoantibodies to monitor vaccine trials

The technology is best suited to the discovery of biomarker panels for cancer and autoantibody diseases.